The Novacyt share price has risen 2,500% this year! Is it worth adding to your ISA?

The Novacyt share price is up! The biotech company is making Covid-19 testing kits for the UK government. But is it worth investing your money in?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At least someone’s having a good time in this pandemic! Whilst most businesses have been hit hard by coronavirus – with countless shops and restaurants closing – a few have thrived. Novacyt (LSE:NCYT) is a biotech company currently producing testing kits for the UK government. As of the end of 2019, the Novacyt share price was 12p. But since rising over 2,500% to almost 500p, the shares are trading around 340p at the time of writing. It seems the company has had new life breathed into it by the huge contracts the pandemic has provided, signing an agreement with some big names in the biotech sector. But does the stock have enough long-term investment merits to warrant investing your cash in?

Putting the Novacyt share price under the microscope

Last year Novacyt reported a loss of £6.5m and earnings per share of -0.12p. That’s not a brilliant start. Obviously, without earnings, the shares do not pay a dividend. Cash flow before financing is also in red territory. The debt ratio has tripled from FY2018 to 2019 and debt to equity is up by 150%. And just to put the boot in, revenues have declined year on year since 2017. From first inspection, Novacyt looks like a company increasingly relying on outside financing to sustain slowly declining sales. But all that data is from the past – when the Novacyt share price was at 12p. Investors have become a lot more excited since then. Let’s see why.

Never let a crisis go to waste

Much of the investor interest stems from Novacyt’s ongoing work on a fast-turnaround testing solution for Covid-19. Called a CE-Mark test, it is designed to allow non-clinical staff to apply fast tests to suspected cases. Additionally, its PCR tests are used to detect antigens, which can determine whether someone has the virus or not. The company quickly established the need to develop significant manufacturing capacity, and today has eight dedicated manufacturing sites capable of producing Covid-19 tests at an output rate of more than 10 million tests per month, which Novacyt expects to achieve from June onwards.

The Directors believe the significant demand for the Company’s Covid-19 test will continue through to the end of the year, and may extend well into 2021, as the global demand for Covid-19 testing continues to increase. Another hope is that the global contacts and networks that will be created during the pandemic will provide access to wider markets for other products in the future. If the company can become consistently profitable, the Novacyt share price could keep climbing.

Looking to the future…

Savvy investors will want to know how Novacyt will continue to make money once the pandemic finally fades into the background. The Directors’ belief that mass Covid-19 testing will continue until 2021 still leaves open the question: what next? Indeed, the demand will fall away at some point. Perhaps when we see a vaccine for Covid-19. The company states that its customer base has significantly increased around the world, and cash has risen from €1.8m as of 31 December 2019 to €9.2m at the end of April. The company has never looked in a healthier position than it does now. It’s no wonder that the Novacyt share price has risen so dramatically! The question is whether they can translate good fortune into a viable business future. If so, Novacyt could represent a good investment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Toby Aston does not own shares in any of the companies mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »